e-learning
resources
European Respiratory Review
2010
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Riociguat: an upcoming therapy in chronic thromboembolic pulmonary hypertension?
Kim N. H.
Source:
Eur Respir Rev 2010; 19: 68-71
Journal Issue:
March 2010 - 19 (115)
Disease area:
Pulmonary vascular diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Kim N. H.. Riociguat: an upcoming therapy in chronic thromboembolic pulmonary hypertension?. Eur Respir Rev 2010; 19: 68-71
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion on ERS Statement – A core outcome set for clinical trials evaluating the management of COPD exacerbations
ERS statement: a core outcome set for clinical trials evaluating the management of COPD exacerbations
The definition of pulmonary hypertension: history, practical implications and current controversies
Related content which might interest you:
Soluble guanylate cyclase stimulation: an emerging option in pulmonary hypertension therapy
Source: Eur Respir Rev 2009; 18: 35-41
Year: 2009
The efficacy of bosentan in inoperable chronic thromboembolic pulmonary hypertension: a 1-year follow-up study
Source: Eur Respir J 2006; 28: 138-143
Year: 2006
Long-term treatment with sildenafil in chronic thromboembolic pulmonary hypertension
Source: Eur Respir J 2007; 30: 922-927
Year: 2007
RESPITE: Riociguat in pulmonary arterial hypertension patients with an inadequate response to phosphodiesterase type 5 inhibitors
Source: International Congress 2016 – Clinic of pulmonary hypertension
Year: 2016
Acute hemodynamic effects of riociguat in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension
Source: International Congress 2018 – Pulmonary hypertension: therapy
Year: 2018
Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: a phase II study
Source: Eur Respir J 2010; 36: 792-799
Year: 2010
Riociguat for interstitial lung disease and pulmonary hypertension: a pilot trial
Source: Eur Respir J 2013; 41: 853-860
Year: 2013
Vasodilator treatment in chronic thromboembolic pulmonary hypertension
Source: Annual Congress 2003 - Update on chronic thromboembolic pulmonary hypertension
Year: 2003
Continuous intravenous epoprostenol for chronic thromboembolic pulmonary hypertension
Source: Eur Respir J 2004; 23: 595-600
Year: 2004
ERS statement on chronic thromboembolic pulmonary hypertension
Source: ERS webinar 2021: ERS statement on chronic thromboembolic pulmonary hypertension
Year: 2021
Improvement of exercise capacity in monocrotaline induced pulmonary hypertension by the phosphodiesterase inhibitor Vardenafil
Source: Annual Congress 2006 - Signalisation in the pulmonary vasculature: new pathways and wrong signals
Year: 2006
Effect of riociguat on haemodynamic parameters and exercise capacity in patients with chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension (PAH)
Source: Annual Congress 2009 - Clinical management of pulmonary arterial hypertension
Year: 2009
Surgical and post-operative treatment of chronic thromboembolic pulmonary hypertension
Source: Eur Respir Rev 2009; 19: 64-67
Year: 2010
Bosentan for inoperable chronic thromboembolic pulmonary hypertension
Source: Eur Respir J 2006; 28: Suppl. 50, 399s
Year: 2006
Pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: pathophysiology
Source: Eur Respir Rev 2009; 19: 59-63
Year: 2010
Chronic thromboembolic pulmonary hypertension: role of medical therapy
Source: Eur Respir J 2013; 41: 985-990
Year: 2013
Managing chronic thromboembolic pulmonary hypertension: pharmacological treatment options
Source: Eur Respir Rev 2009; 18: 24-28
Year: 2009
Riociguat for the treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: Real-life data from the EXPERT registry
Source: International Congress 2015 – Pulmonary hypertension: new treatment insights
Year: 2015
Chronic thromboembolic pulmonary hypertension
Source: Eur Respir Mon 2012; 57: 108-118
Year: 2012
Pharmacological therapy for patients with chronic thromboembolic pulmonary hypertension
Source: Eur Respir Rev 2015; 24: 272-282
Year: 2015
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept